Takada et al. developed a prediction model for pCR after NCT using ADTree,8 in which the fluorouracil, epirubicin, and cyclophosphamide (FEC) regimen was used for the whole study population; however, they failed to take into account the use of targeted drugs in patients with HER2+ breast cancer. This evidence concerns the gene ERBB2 and breast cancer.